MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,110.00
-120.00 (-3.72%)
Mar 28, 2025, 3:30 PM KST
-77.46%
Market Cap 106.60B
Revenue (ttm) n/a
Net Income (ttm) -20.14B
Shares Out 34.28M
EPS (ttm) -598.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 173,758
Average Volume 207,716
Open 3,230.00
Previous Close 3,230.00
Day's Range 3,050.00 - 3,240.00
52-Week Range 3,050.00 - 13,720.00
Beta 0.87
RSI 34.93
Earnings Date Mar 19, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Employees 56
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.